查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1736516

全球炭疽疫苗市场 - 市场规模（按产品类型、应用、最终用户、地区、预测）

Global Anthrax Vaccines Market Size By Product Type (Cell-Free PA Vaccines, Live Cells), By Application (Animal Use, Human Use), By End-User (Hospital Pharmacy, Retail pharmacy), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 | 商品交期: 2-3个工作天内

价格
简介目录

炭疽疫苗市场规模及预测

2024 年炭疽疫苗市场规模为 131.7 亿美元，预计到 2032 年将达到 292.7 亿美元，2026 年至 2032 年的复合年增长率为 5.59%。

由于炭疽疫情的增多，全球炭疽疫苗市场正快速成长。炭疽疫苗市场的成长动力源自于未煮熟的病畜肉和生肉消费量的增加。此外，生皮和毛纺织物等受​​污染商品的工业或製造加工也促进了市场的成长。全球炭疽疫苗市场报告提供了市场的整体评估，全面分析了关键细分市场、趋势、市场驱动因素、限制、竞争格局以及影响市场的关键因素。

定义炭疽疫苗的全球市场

炭疽病是由炭疽菌引起的一种危险感染疾病。目前已有疫苗可以预防。但这种疫苗通常不会向公众提供。它只适用于感染炭疽病风险高或已经接触炭疽菌炭疽菌的人。炭疽病是由革兰氏阳性细菌炭疽菌孢子引起的一种严重感染疾病。感染途径主要有四种：肺部、肠道、皮肤和注射。人类和动物都容易受到炭疽菌感染，尤其是牛、羊、山羊和马等反刍动物。炭疽菌很难在人与人之间传播。

炭疽病的症状和征兆因感染类型而异。皮肤炭疽病、胃肠道炭疽病、吸入性炭疽病和注射性炭疽病的症状各不相同。胃肠道炭疽病最常见的症状是噁心、腹痛、食慾不振、呕吐、发烧、血性腹泻、颈部肿胀、头痛和吞嚥困难。吸入性炭疽病可能导致呼吸急促、咳血、吞嚥困难、轻微胸部不适和噁心。注射性炭疽病最常见的征兆和症状是多重器官衰竭、脑膜炎和注射部位周围发红。

目前，世界各地炭疽病的诊断方法是检体患者血液中是否有抗体或毒素。此外，医学专家建议进行直接检测以诊断是否感染炭疽菌。炭疽菌疫苗有无细胞疫苗和活病毒疫苗两种形式。接种炭疽菌疫苗的主要原因是吸入感染的风险。作为暴露前疫苗，使用无细胞疫苗（炭疽疫苗吸附剂，AVA），该疫苗含有炭疽毒素成分，接种 3 至 6 剂后可提供保护性免疫。沉淀炭疽疫苗（AVP）初次接种三次，6 个月后加强接种。每 12 个月需要接种一次加强剂以诱导和维持保护性免疫。

目前的炭疽疫苗在局部和全球范围内都具有高度反应性（红斑、硬结、疼痛、发热）。约1%的疫苗接种有严重的副作用。重组活病毒疫苗次单位疫苗疫苗是目前正在研发的两种新型第二代疫苗。炭疽疫苗吸附剂（AVA）或BioThraxTM是唯一获得许可的炭疽疫苗，建议用于18至65岁炭疽菌高危险群的主动免疫接种，以预防炭疽菌。位于密西根州兰辛的Emergent BioDefense Operations Lansing Inc.自1970年以来已获得生产该疫苗的许可。目前有多家公司正在研发下一代炭疽疫苗。

全球炭疽疫苗市场概况

由于炭疽菌发病率不断上升，炭疽疫苗市场蓬勃发展。全球市场的主要驱动力是食用生的和未煮熟的感染动物肉的现像日益流行。此外，毛纺织物和皮革等受污染动物产品的商业性和工业加工大幅增加也推动了市场的成长。炭疽菌最常见于野生动物和家畜。随着世界各地畜牧业的兴起，农场的数量也增加。在农场工作使人们与动物近距离接触，使他们面临感染炭疽菌的风险。这个因素是市场的主要驱动力。

同时，炭疽病自愿筛检率低可能是炭疽疫苗市场发展的一大障碍。此外，非洲等地区对炭疽菌诊断检测缺乏了解，导致企业难以直接接触客户，阻碍了市场成长。炭疽菌患病率上升以及未煮熟和生肉消费量增加等因素是市场成长的主要驱动力。透过改善诊断、监测和疫情应对措施，可以预防动物和人类感染炭疽病。此疾病的高发生率、感染风险和严重程度使其成为预防保健机构的首要任务之一。

炭疽菌是透过食用受感染的肉类在动物体内传播的。儘管鸡肉、牛肉和猪肉的消费模式差异很大，但所有这些消费模式都会增加炭疽病的风险。鑑于上述情况，炭疽疫苗市场在预测期内可能会扩大。该市场由少数参与者主导，预计在预测期内可能会有所发展，然而，缺乏对诊断和筛检检测的认识以及炭疽疫苗价格过高等因素可能会阻碍市场扩张。

目录

第一章全球炭疽疫苗市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章炭疽疫苗全球市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球炭疽疫苗市场（依产品类型）

  • 概述
  • 无细胞PA疫苗
    • AVA
    • AVP
  • 活细胞

6. 全球炭疽疫苗市场（依应用）

  • 概述
  • 对人类来说
  • 对于动物

7. 全球炭疽疫苗市场（依最终用户）

  • 概述
  • 医院药房
  • 零售药局
  • 其他的

8. 全球炭疽疫苗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

9. 全球炭疽疫苗市场竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第十章 公司简介

  • Zoetis Inc.
  • Emergent Bio-Solutions
  • Merck & Co. Inc.
  • Colorado Serum
  • PharmaAthene Inc.
  • Vecol
  • Biogenesis Bago Inc.
  • Porton Biopharma Inc.
  • Merial
  • Intervac

第十一章 重大进展

  • 产品发布/开发
  • 合併与收购
  • 业务扩展
  • 伙伴关係与合作

第十二章 附录

  • 相关调查
简介目录
Product Code: 37346

Anthrax Vaccines Market Size And Forecast

Anthrax Vaccines Market size was valued at USD 13.17 Billion in 2024 and is projected to reach USD 29.27 Billion by 2032, growing at a CAGR of 5.59 % during the forecast period 2026-2032.

Because of the rising prevalence of the disease, the global market for anthrax vaccinations is rapidly growing. The market for anthrax vaccinations is driven by the increased consumption of undercooked or raw meat from diseased animals. Increased industrial or manufacturing processing of contaminated commodities like skins and hair wool will also help to grow the market. The Global Anthrax Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Anthrax Vaccines Market Definition

Anthrax is a dangerous infection caused by the bacteria Bacillus anthracis. There is a vaccination that can help avoid it. This vaccination, however, is not normally available to the general population. It is only indicated for persons who are at a high risk of contracting B. anthracis or who have already been exposed to it. Anthrax is a serious infectious disease caused by the spores of Bacillus anthracis, a gram-positive bacterium. The lungs, intestines, skin, and injectables are the four main routes of infection. Both humans and animals are susceptible to anthrax, particularly ruminants like cattle, sheep, goats, and horses. It is difficult to spread from one individual to another.

Anthrax symptoms and signs differ based on the type of infection. The symptoms of cutaneous anthrax, gastrointestinal anthrax, inhalation anthrax, and injectable anthrax differ. The most common signs and symptoms of gastrointestinal anthrax include nausea, abdominal pain, lack of appetite, vomiting, fever, bloody diarrhea, swelling neck, headache, and difficulty swallowing. Inhalation anthrax causes shortness of breath, blood in the cough, uncomfortable swallowing, minor chest discomfort, and nausea. The most common indications and symptoms of injectable anthrax are multiple organ failure, meningitis, and redness around the injection site.

Currently, the primary approaches in the diagnosis of anthrax available worldwide rely on the presence or absence of antibodies or toxins in a patient's blood sample. Furthermore, healthcare professionals advised using direct testing to diagnose the presence of Bacillus anthracis. Anthrax vaccinations are available in both cell-free and live forms. The main reason for anthrax immunization is the danger of infection through inhalation. An acellular vaccine (anthrax vaccine adsorbed or AVA), which contains anthrax toxin components and results in protective immunity after 3 to 6 doses, is used as a pre-exposure vaccine. Anthrax vaccine precipitated (AVP) is given in three doses at prime vaccination, with a booster dose 6 months later. A booster dose is required once every 12 months to elicit and sustain protective immunity.

Current anthrax vaccinations have a high level of local and overall reactogenicity (erythema, induration, soreness, fever). About 1% of immunizations have serious side effects. Recombinant live vaccines and recombinant sub-unit vaccines are the two new second-generation vaccines that are currently in development. Anthrax Vaccine Adsorbed (AVA) or BioThraxTM, the only licensed anthrax vaccine, is recommended for active vaccination for the prevention of disease caused by Bacillus anthracis in those aged 18 to 65 who are at a high risk of exposure. Emergent BioDefense Operations Lansing Inc. in Lansing, Michigan, has been licensed to manufacture the vaccine since 1970. Multiple companies are working on next-generation anthrax vaccinations.

Global Anthrax Vaccines Market Overview

Because of the rising occurrence of anthrax, the Anthrax Vaccines Market is fast growing. A major driver of the global market is the rise in popularity of eating raw and undercooked meat from infected animals. Furthermore, a large increase in the commercial and industrial processing of contaminated animal commodities such as hair wool, and hide boosted the market growth. Anthrax is most commonly seen in wild wildlife and livestock. The number of farms is growing as animal husbandry becomes more popular around the world. Working on farms puts people in close proximity to animals, putting them at risk of contracting anthrax. This element operates as the market's primary driving force.

The low percentage of voluntarily screening for anthrax disease, on the other hand, could be a major impediment to the Anthrax Vaccines Market. Furthermore, in places like Africa, a lack of understanding regarding anthrax diagnostic tests makes it difficult for companies to reach out directly to their clients, stifling market growth. Factors such as the rising prevalence of anthrax and the expanding consumption of undercooked or raw meat are mostly to blame for the market's expansion. It may be possible to avoid it in both animals and humans by improving diagnosis, surveillance, and outbreak response. The disease has a high prevalence rate, and the risk and severity of infection make it one of the top priorities for preventive healthcare organizations.

Anthrax has been found in animals as a result of infected meat. Although the consumption patterns in chicken, beef, and pork are substantially different, they all raise the risk of anthrax. As a result of the foregoing, the Anthrax Vaccines Market is likely to expand over the forecast period. Although the market is dominated by a few players and is likely to develop over the forecast period, factors such as a lack of awareness regarding diagnostic and screening tests and the anthrax vaccine's exorbitant cost may hinder market expansion.

Global Anthrax Vaccines Market Segmentation Analysis

The Global Anthrax Vaccines Market is segmented based on Product Type, Application, End-User, And Geography.

Based on the Product Type, the market is bifurcated into Cell-Free PA Vaccines and Live Cells. Cell-Free PA Vaccines are expected to hold the largest market share in the coming years.

Anthrax Vaccines Market, By Application

  • Animal Use
  • Human UseBased on Application, the market is bifurcated into Animal Use And Human Use. The animal use anthrax vaccination segment is expected to dominate the market. Anthrax is an epizootic disease that spreads from animals to humans and appears in sensitive animals, both wild and domesticated, on a regular basis. Anthrax is acute septicemia with a high fatality rate in herbivore animals such as cattle, sheep, goats, camels, and antelopes. It is generally accompanied by hemorrhagic lymphadenitis. In dogs, pigs, and horses, however, it is a less severe but possibly lethal condition.

Anthrax Vaccines Market, By End-User

  • Hospital Pharmacy
  • Retail pharmacy
  • Others

Based on End-User, the market is bifurcated into Hospital Pharmacy, Retail pharmacy, and Others. Hospital pharmacies dominated the market. Hospitals serve as a key immunization venue, which explains why anthrax vaccine sales are so high there. Anthrax vaccines are, additionally, routinely administered to patients in hospitals.

Anthrax Vaccines Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Geography, the Global Anthrax Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America owing to the growing number of anthrax patients.

Key Players

The "Global Anthrax Vaccines Market" study report will provide a valuable insight with an emphasis on global market including some of the major players such as Zoetis Inc., Emergent Bio-Solutions, Merck & Co. Inc., Colorado Serum, PharmaAthene Inc., Vecol, Biogenesis Bago Inc., Porton Biopharma Inc., Merial, and Intervac.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In August 2020, Anthim (obiltoxaximab for injection), a monoclonal antibody (mAb) anthrax antitoxin, developed by Elusys Therapeutics Inc. (Elusys), obtained approval from Health Canada for the treatment of inhalation anthrax and can be used to treat post-exposure prophylaxis in both adults and children.
  • In August 2020, Dr. Jamie Benn Felix and the Cook Wildlife Lab team from Texas A&M University College of Veterinary Medicine & Biomedical Sciences performed pilot research for the first oral anthrax vaccine for livestock (CVMBS).

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ANTHRAX VACCINES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL ANTHRAX VACCINES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL ANTHRAX VACCINES MARKET, BY PRODUCT TYPE

  • 5.1 Overview
  • 5.2 Cell-Free PA Vaccines
    • 5.2.1 Anthrax Vaccine Adsorbed (AVA)
    • 5.2.2 Anthrax Vaccine Precipitated (AVP)
  • 5.3 Live Cells

6 GLOBAL ANTHRAX VACCINES MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Human Use
  • 6.3 Animal Use

7 GLOBAL ANTHRAX VACCINES MARKET, BY END-USER

  • 7.1 Overview
  • 7.2 Hospital Pharmacy
  • 7.3 Retail pharmacy
  • 7.4 Others

8 GLOBAL ANTHRAX VACCINES MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL ANTHRAX VACCINES MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Zoetis Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Emergent Bio-Solutions
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Merck & Co. Inc.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Colorado Serum
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 PharmaAthene Inc.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Vecol
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Biogenesis Bago Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Porton Biopharma Inc.
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Merial
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Intervac
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research